维康药业 reported revenue of ¥0.13B for the period ended 2026-06-30, +10.1% year on year. Net income was ¥-0.02B, a -17.6% net margin on a 40.2% gross margin. The largest revenue line is 药品销售 at 96% of the total. Free cash flow for the period was ¥-0.00B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.13B | +10.1% |
| Gross profit | ¥0.05B | — |
| Operating income | ¥-0.02B | — |
| Net income | ¥-0.02B | — |
| Gross margin | 40.2% | Net margin -17.6% |
| Revenue Q/Q | -18.9% | — |
| Segment | Revenue | Share |
|---|---|---|
| 药品销售 | ¥0.12B | 96.2% |
| 医疗服务 | ¥0.00B | 2.0% |
| 其他主营业务 | ¥0.00B | 1.8% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.08B | 59.8% |
| R&D | ¥0.00B | 3.4% |
| SG&A | ¥0.06B | 43.6% |
| Tax & other | ¥0.01B | 4.3% |
| Item | Amount |
|---|---|
| Total assets | ¥1.27B |
| Total liabilities | ¥0.37B |
| Shareholders' equity | ¥0.90B |
| Equity / assets | 71.1% |
| Operating cash flow | ¥-0.00B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥-0.00B |
| Cash conversion (OCF / net income) | 111% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
大叶股份 ・ 迦南智能 ・ 盛德鑫泰 ・ 万胜智能 ・ 龙利得 ・ 狄耐克 ・ 海昌新材 ・ 华业香料 ・ 谱尼测试 ・ 稳健医疗 ・ 爱克股份 ・ 翔丰华
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies